AFFY:OTC-Affymax, Inc (USD)

COMMON STOCK | Biotechnology | OTC

Last Closing Price

USD 0.03

Change

+0.01 (+50.00)%

Market Cap

USD 2.89M

Volume

0.02M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Affymax, Inc. does not have significant operations. Previously, it was developing drugs to enhance the treatment of serious and often life-threatening conditions in the United States. The company was founded in 2001 and is based in New York, New York.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-31 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NONOF Novo Nordisk A/S

N/A

USD137.81B 22.42 N/A
CSLLY CSL Limited

-5.35 (-5.53%)

USD85.32B 43.81 29.06
CMXHF CSL Limited

N/A

USD77.36B 39.56 30.68
SBMFF Sino Biopharmaceutical Limited

N/A

USD17.24B 41.21 N/A
SBHMY Sino Biopharmaceutical Limited

N/A

USD17.24B 37.88 N/A
UCBJY UCB SA

N/A

USD15.61B 18.16 N/A
UCBJF UCB SA

+3.26 (+3.89%)

USD15.61B 15.52 N/A
GNMSF Genmab A/S

-5.90 (-2.95%)

USD12.40B 55.74 N/A
BBAGF BB Biotech AG

+250.00 (+500.00%)

USD3.98B 5.30 -20.60
PPTDF PeptiDream Inc

-4.02 (-10.78%)

USD3.97B 235.91 N/A

ETFs Containing AFFY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 42.86% 78% C+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 42.86% 78% C+ 87% B+
Trailing 5 Years  
Capital Gain -73.24% 46% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -73.24% 45% F 26% F
Average Annual (5 Year Horizon)  
Capital Gain -18.18% 19% F 9% F
Dividend Return N/A 40% F 12% F
Total Return -18.18% 19% F 9% F
Risk Return Profile  
Volatility (Standard Deviation) 48.90% 69% D+ 52% F
Risk Adjusted Return -37.17% 20% F 12% F
Market Capitalization 2.89M 38% F 32% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 0.26 92% A- 96% A
Price/Book Ratio 0.15 91% A- 82% B-
Price / Cash Flow Ratio -0.04 22% F 54% F
EV/EBITDA 0.06 8% F 37% F
Management Effectiveness  
Return on Equity 111.59% 99% A+ 99% A+
Return on Invested Capital -456.89% 8% F 3% F
Return on Assets -228.91% 20% F 7% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.35 35% F 31% F
Short Percent 49.35% 5% F 10% F
Beta 2.55 15% F 15% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters then its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.